from program, delivery that progress we and delivery BioJet Thanks, tox program with much Kristy. completing this ago, on With our last are we continued BT-XXX have development with And analysis made our device platform, encouraging. our weeks thank data you, X executing NaviCap-targeted everyone, plans for double in our joining us. top present results excellent we of of systemic call Since study from development We're the an on for our also to using testing target biogen detailed progressed bioavailability planning an to results of we than that BioJet preclinical autonomous pharma with upcoming shared platform medical results studies our at line next-generation rapidly our were Based our bioavailability more conference. one collaborators. March preclinical levels, began version device. in the
Finally, Kelman Officer, we to is we with clinic clinical year. addition the Medical as good Chief prepare Dr. timing Ariella our this which team enter strengthened of the as
the program updates. on to Moving
NaviCap-targeted First, ulcerative program, available or of therapeutics disease UC, lead amount throughout the BT-XXX a for our by colon. bloodstream circulated limited the reaching with in ulcerative of cover therapeutics colitis. and systemically the platform our work Currently entering with the body I'll drug being colitis, in site
the the of drug our solution the platform, that size based is which pill uses ingestible Our designed oil on a to fish technology. track device localization colon is NaviCap an deliver GI using about orally to directly
UC. BT-XXX, tofacitinib commercially is the disease, A proprietary up to amount in like it targeted of tofacitinib potential drug reaching of orally delivered may area approved of the to needed available where drug By improve limited reduce delivering liquid and has the systemic at for NaviCap Today, is colon. improve the the the lead our also sufficient Our systemically the of exposure, treatment version drugs, administered the site deliver area safety. and tissue with via is device. orally other formulation taken delivered tofacitinib has of program, of it a to efficacy which disease BT-XXX is
need. growing, suffering large approximately Although and tremendously patients we unmet with know for a billion year still global sales drugs are UC UC per $X are
At then, call study XXX administered, of tissue primary why look in our toxicity. no completed we drug inability without devices continue have events we solve we were a the over we All the during received the results time we believe the BT-XXX, good. can from adverse and enough the the canines. in administered about to study we're excited Since data seeing safety for disease execution of That's the for which signals. and high of planned observed of majority in which toxicology We treatment drug our the one last systemic is achieve recently device had combinations potentially we're or to toxicology results gaps BT-XXX. March, levels that
Of particular chemistry tofacitinib. dose no on including the the histopathology tests, were note, function liver there blood colon on highest safety safety XX-milligram or of at and findings of tests, even
the drug doses last improve suggesting not is XX With colon of reducing X drug and levels, see the drug want that tissue, another because drug to high In dose the levels we with it is administration to going NaviCap this exposure platform, levels is to we down achieve in last accumulating. at of the to these sign but we previous and over and levels canine study, after want levels look study, When which the ICXX, in saw the and colon is see. at of safety. dose in in concentrations tissue between our our blood, we hours measured can tissue what want In safety. drug systemic concentrations blood, that hours saw we and measure tissues at time, XX believed low after drug levels which not favorable some see in tissue drug X-day we does accumulate administration exceeding tox goal the
also dose supports levels receiving This study, continue of efficacy Final levels we planned of approximately to toxicity. of audited BT-XXX drug further aggregate, quarter aspects track having of and exposure and remain expected QX. at to available drug on the recent potentially to traditional of ability well we program, studies reduce administration. be desired high lower systemic dissipate oral is ongoing, In to the our the peak enough tracking tissue safety. approach time tofacitinib we still using then analysis see of commercially in the to what short of would Taken toxicology anticipate to and X report in in IND We're blood a support in with equivalent colon on with for in concentrations potentially deliver progress the weeks. we the the coming currently other our filing support believe these drive
Ariella over into Chief that experience Kelman XX-plus IND late-stage for development broad joined be Genentech and prepare strengthening has as bringing years Medical of dozens our Dr. announced also then and We valuable immunologist clinical experience programs an BT-XXX her therapeutics program for file and and background development. as will with early-stage as of Biora medical progress our Officer, of we our later valuable Ariella's stages team. to recently
based believe we which will provides of on injection platform could BioJet to management biotherapeutics, platform therapeutics that and can shown and this improve patient an nucleic These costs would The patient aims improve oral of been facilitate more acid compliance. BioJet Moving as orally disease monoclonals, or with the improvements delivery The intravenous affect of the on jet potential We and peptides require to intestine without Most small associated our a systemic maximize molecules, systemic convenience, such systemic has to of The device BioJet alternatives. also outcomes all, delivery competitive liquid platform help across deliver indications. believe become patient that infusion a is this drugs uptake. large otherwise proteins, platform. to range injectable such infusion. range ingestible to reduce broad complex to reformulation. chronic as use platform has help
June. this a drugs: from to preclinical I'm a adalimumab, line achieve and we of announced agonist. the think sharing share monoclonal at agonist from as We other that top abstract bioavailability excited the ADA target Sessions. large delivery semaglutide, a GLPX interest forward of as accepted abstract scientific two meeting results studies In late-breaking American double in Association with and molecules. We using community semaglutide, data look breaker the more acceptance by preclinical oral with QX, indicates peptide upcoming BioJet and we the study Scientific study late results than study antibody a from at During Diabetes receptor the the the to detailed our tremendous platform. GLP-X this was in
collaborator, preclinical that updates Ionis a endoscopically BioJet of soon We're on conducted and recently Pharmaceuticals oligonucleotide using as an molecule. awaiting to. testing round with more an study, as share able our activated results antisense we're device Ionis we'll with We of
also autonomously an weeks In call, the we've testing few preclinical short since BioJet with device. conducted triggered last our
partnerships to platform collaborators progressing to pharma through for track coming believe to the data and with we weeks, other remain BioJet testing of QX these our year. our continue on during we achieving own We advancing X that forward enable initiate and our generate molecules. to expect are meaningful look this testing later toward their goal necessary to We collaborations
see the due time over platform of molecules. for applicability to continue different We the multiple broad partnerships BioJet potential to to
using in for is platform patent granted a covers a for patent reminder, to a position methods aspect GLP-X which delivery small very achieve our uptake. the treat intestine puts ingestible delivery formulation BioJet As comprehensive Jet last condition to using position Biora one a key oral strong systemic device for a to year, providing of of the GLP-Xs. an of competitive agonist receptor This
upward the within and analyst projections next billion for Ozempic seeing the Mounjaro, the drugs we're being $XXX market With of to success like XX GLP-X revised annually years.
anticipated for To summarize milestones both platforms. our
QX, filing and to the BT-XXX Phase year. end for platform, initiating the I remain in trial for our we For we IND an anticipate NaviCap committed of our
during For of autonomous generation the continuing preclinical BioJet expected platform, our BioJet we're with quarter additional of device development our data XXXX. second
of the and test of molecules testing our pharma initiate to device continue to expect of also BioJet new the We collaborators.
results Association also the look with sharing on Diabetes to forward for 'XX. semaglutide our Scientific We preclinical Sessions American at study BioJet June
our With that, the now Eric activities. to and a results over call I'll market review capital of for turn financial
